Evotec (NASDAQ:EVO) Shares Cross Above 50 Day Moving Average - Here's What Happened

Key Points

• Evotec shares rose 13.1% and crossed above their 50-day moving average of $1.62, reaching $1.82 before last trading at $1.775.
• Q3 revenue was €164.9 million, beating analyst expectations, while the adjusted EBITDA loss narrowed to €1.6 million. Evotec reaffirmed its FY2026 guidance and reported 24% growth in D&PD base-business net sales.
• The longer-term outlook remains mixed: Evotec lowered and slightly delayed its 2030 revenue ambitions, while analysts’ average rating is Hold with a $3 target price.

Evotec AG (NASDAQ:EVO - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $1.62 and traded as high as $1.82. Evotec shares last traded at $1.7750, with a volume of 273,618 shares.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Evotec’s Q3 adjusted EBITDA loss narrowed to €1.6 million. Revenue was €164.9 million, and the company also beat analyst expectations for quarterly revenue and EPS. Evotec Q3 and nine-month results
• Positive Sentiment: The company reaffirmed its FY2026 guidance. It also reported 24% growth in D&PD base-business net sales, pointing to commercial momentum. Evotec Q3 EBITDA and guidance
• Neutral Sentiment: Evotec highlighted a new Vertex manufacturing mandate, which could support future business, though the articles provided no financial details about the contract. Vertex manufacturing mandate and RBC target
• Negative Sentiment: Evotec cut and slightly postponed its 2030 revenue ambitions, tempering the longer-term growth outlook despite the quarterly improvement. Evotec cuts 2030 revenue target
• Negative Sentiment: RBC reduced its price target to €5, adding to investor concerns about the outlook. A report also noted a reduced JPMorgan stake, though the supplied details do not specify the size or rationale. Analyst target and JPMorgan stake report

Wall Street Analyst Weigh In

Several research firms have recently commented on EVO. HC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Evotec in a report on Wednesday, October 14th. Weiss Ratings lowered Evotec from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 25th. Berenberg Bank lowered Evotec from a "buy" rating to a "hold" rating in a research report on Thursday, July 16th. Finally, TD Cowen downgraded Evotec from a "buy" rating to a "hold" rating and set a $2.00 price objective for the company. in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $3.00.

Evotec Trading Up 13.1%

The business has a fifty day moving average of $1.62 and a 200-day moving average of $2.49. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC acquired a new position in Evotec in the 1st quarter worth about $28,000. Optiver Holding B.V. lifted its holdings in shares of Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company's stock valued at $709,000 after buying an additional 242,973 shares during the last quarter. Finally, WCM Investment Management LLC lifted its holdings in shares of Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company's stock valued at $1,480,000 after buying an additional 67,917 shares during the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec's activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.